Geriatric outcomes among older Type 2 diabetic patients treated with DPP4 inhibitors or glinides: focus on pro-inflammatory and oxidative stress markers (GOOD-WP1)
Latest Information Update: 20 Dec 2022
At a glance
- Drugs Linagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms GOOD-WP1
Most Recent Events
- 20 Dec 2022 The trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 05 Sep 2022 Planned End Date changed to 19 Feb 2021.
- 03 Sep 2022 New trial record